Hsc Dental Llc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 2355 American Legion Blvd, Mountain Home, ID 83647 Phone: 208-587-7949 |
Dental Center P.l.l.c. Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 815 N 6th E, Mountain Home, ID 83647 Phone: 208-587-7949 Fax: 208-587-2978 |
John E. Goodrich, D.d.s. Dentist Medicare: Not Enrolled in Medicare Practice Location: 450 Airbase Rd, Mountain Home, ID 83647 Phone: 208-587-3314 Fax: 208-587-3921 |
Playhouse Dentistry For Kids Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 125 S 10th E, Mountain Home, ID 83647 Phone: 208-453-6188 |
Mountain Home Dental Pc Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 455 N 3rd E, Mountain Home, ID 83647 Phone: 208-587-2625 |
Desert Sage Health Center Dentist Medicare: Not Enrolled in Medicare Practice Location: 2280 American Legion Blvd, Mountain Home, ID 83647 Phone: 208-587-3988 |
News Archive
Creutzfeldt-Jakob disease (CJD)- the human equivalent of mad cow disease- is caused by rogue, misfolded protein aggregates termed prions, which are infectious and cause fatal damages in the patient's brain. CJD patients develop signature microscopic sponge-like holes in their brains.
Recent studies have shown that palliative care interventions aimed at addressing patients' emotional, spiritual and social needs have a significant impact on cancer patients' quality of life and may even improve cancer patients' overall survival. Despite this, most cancer patients being cared for in their communities do not have access to these services.
Cardiovascular genetic testing in children presents unique challenges, requiring pre- and post-test counseling with an individualized approach for families.
Children with cancer could be spared dozens of doses of general anesthesia by projecting a video directly onto the inside of a radiotherapy machine during treatment, according to research presented at the ESTRO 36 conference.
Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.
› Verified 1 days ago